Patents by Inventor Jacob Westman

Jacob Westman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240140921
    Abstract: There is provided an alkali metal salt of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide and formulations thereof. This salt finds particular utility in the treatment or prevention of a disorder or condition ameliorated by the activation of AMPK.
    Type: Application
    Filed: May 15, 2023
    Publication date: May 2, 2024
    Applicant: Betagenon AB
    Inventors: Thomas EDLUND, Jacob WESTMAN
  • Publication number: 20240124480
    Abstract: The present document is directed to methods for producing therapeutically active limonoids as well as new limonoid-type compounds.
    Type: Application
    Filed: September 19, 2023
    Publication date: April 18, 2024
    Inventors: Jacob Westman, Catarina Malmberg
  • Publication number: 20240124482
    Abstract: The present document is directed to methods for producing therapeutically active limonoids as well as new limonoid-type compounds.
    Type: Application
    Filed: October 27, 2023
    Publication date: April 18, 2024
    Inventors: Jacob Westman, Catarina Malmberg
  • Publication number: 20240124481
    Abstract: The present document is directed to methods for producing therapeutically active limonoids as well as new limonoid-type compounds.
    Type: Application
    Filed: October 27, 2023
    Publication date: April 18, 2024
    Inventors: Jacob Westman, Catarina Malmberg
  • Publication number: 20240082222
    Abstract: This invention relates to a new method of activating 5? adenosine monophosphate-activated protein kinase (AMPK) to treat certain diseases and disorders using a salt of 4-chloro-N[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide in a dose-efficient manner. Diseases that may be treated in this way include type-2 diabetes.
    Type: Application
    Filed: January 11, 2022
    Publication date: March 14, 2024
    Applicant: Betagenon AB
    Inventors: Thomas EDLUND, Jacob WESTMAN
  • Publication number: 20230382930
    Abstract: The invention relates to a compound of formula I, wherein: R1 is as defined in the specification, or a pharmaceutically acceptable salt or solvate thereof, which compounds are useful in the treatment treatment of a disorder or condition ameliorated by the activation of AMPK, particarly as prodrugs.
    Type: Application
    Filed: September 30, 2021
    Publication date: November 30, 2023
    Applicant: Betagenon Bio AB
    Inventors: Thomas EDLUND, Jacob WESTMAN
  • Patent number: 11691954
    Abstract: There is provided an alkali metal salt of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide and formulations thereof. This salt finds particular utility in the treatment or prevention of a disorder or condition ameliorated by the activation of AMPK.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: July 4, 2023
    Assignee: BETAGENON AB
    Inventors: Thomas Edlund, Jacob Westman
  • Publication number: 20230096218
    Abstract: There is provided an alkali metal salt of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1, 2,4-thiadiazol-5-yl]benzamide and formulations thereof. This salt finds particular utility in the treatment or prevention of a disorder or condition ameliorated by the activation of AMPK.
    Type: Application
    Filed: October 16, 2020
    Publication date: March 30, 2023
    Inventors: Thomas EDLUND, Jacob WESTMAN
  • Publication number: 20220267287
    Abstract: There is provided an alkali metal salt of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide and formulations thereof. This salt finds particular utility in the treatment or prevention of a disorder or condition ameliorated by the activation of AMPK.
    Type: Application
    Filed: May 6, 2022
    Publication date: August 25, 2022
    Inventors: Thomas Edlund, Jacob Westman
  • Publication number: 20210340147
    Abstract: The compound is useful in therapy, in particular as an antiviral agent, e.g. in the treatment of an RNA viral infection. A pharmaceutical composition comprising the compound.
    Type: Application
    Filed: August 20, 2019
    Publication date: November 4, 2021
    Inventor: Jacob WESTMAN
  • Patent number: 11001587
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, useful in therapy, in particular in the treatment of a viral infection or a disease linked to impaired or abnormal autophagy.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: May 11, 2021
    Assignee: CUROVIR AB
    Inventor: Jacob Westman
  • Publication number: 20200031833
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, useful in therapy, in particular in the treatment of a viral infection or a disease linked to impaired or abnormal autophagy.
    Type: Application
    Filed: April 4, 2018
    Publication date: January 30, 2020
    Inventor: Jacob WESTMAN
  • Patent number: 10407429
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, useful in therapy, in particular in the treatment of a viral infection.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: September 10, 2019
    Assignee: Curovir AB
    Inventor: Jacob Westman
  • Publication number: 20180298007
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, useful in therapy, in particular in the treatment of a viral infection.
    Type: Application
    Filed: June 10, 2016
    Publication date: October 18, 2018
    Applicant: Curovir AB
    Inventor: Jacob WESTMAN
  • Patent number: 9963455
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, useful in therapy, in particular in the treatment of a viral infection.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: May 8, 2018
    Assignee: Curovir AB
    Inventor: Jacob Westman
  • Patent number: 9675596
    Abstract: According to the invention there is provided a compound of formula (I) wherein: A represents C(?N—W-D) or S; B represents S or C(—NH—W-D); when: A represents C(?N—W-D) and B represents S then the bond between B and the NH atom is a single bond; or A represents S and B represents C(—NH—W-D) then the bond between B and the NH atom is a double bond; X represents -Q-[CRxRy]n—; W represents —[CRxRy]m— or —C(O)—[CRxRy]p—; Q represents a bond, —N(Ra)—; —S—, or —O—; A1 to A5 respectively represent C(R1), C(R2), C(R3), C(R4) and C(R5), or, alternatively, up to two of A1 to A5 may independently represent N; D represents phenyl, pyridyl or pyrimidinyl optionally substituted by one or more R6 groups, which compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: June 13, 2017
    Assignee: Baltic Bio AB
    Inventors: Jacob Westman, Allan Hallett, Jan Vagberg
  • Publication number: 20160318937
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, useful in therapy, in particular in the treatment of a viral infection.
    Type: Application
    Filed: January 21, 2015
    Publication date: November 3, 2016
    Inventor: Jacob WESTMAN
  • Publication number: 20160128993
    Abstract: According to the invention there is provided a compound of formula (I) wherein: A represents C(?N—W-D) or S; B represents S or C(—NH—W-D); when: A represents C(?N—W-D) and B represents S then the bond between B and the NH atom is a single bond; or A represents S and B represents C(—NH—W-D) then the bond between B and the NH atom is a double bond; X represents -Q-[CRxRy]n—; W represents —[CRxRy]m— or —C(O)—[CRxRy]p—; Q represents a bond, —N(Ra)—; —S—, or —O—; A1 to A5 respectively represent C(R1), C(R2), C(R3), C(R4) and C(R5), or, alternatively, up to two of A1 to A5 may independently represent N; D represents phenyl, pyridyl or pyrimidinyl optionally substituted by one or more R6 groups, which compounds are useful in the treatment of cancer.
    Type: Application
    Filed: October 14, 2015
    Publication date: May 12, 2016
    Inventors: Jacob Westman, Allan Hallett, Jan Vagberg
  • Patent number: 9162994
    Abstract: According to the invention there is provided a compound of formula (I) wherein: A represents C(?N—W-D) or S; B represents S or C(—NH—W-D); when: A represents C(?N—W-D) and B represents S then the bond between B and the NH atom is a single bond; or A represents S and B represents C(—NH—W-D) then the bond between B and the NH atom is a double bond; X represents -Q-[CRxRy]n—; W represents —[CRxRy]m— or —C(O)—[CRxRy]p—; Q represents a bond, —N(Ra)—, —S—, or —O—; A1 to A5 respectively represent C(R1), C(R2), C(R3), C(R4) and C(R5), or, alternatively, up to two of A1 to A5 may independently represent N; D represents phenyl, pyridyl or pyrimidinyl optionally substituted by one or more R6 groups, which compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: October 20, 2015
    Assignee: BETAGENON AB
    Inventors: Jacob Westman, Allan Hallett, Jan Vågberg
  • Patent number: 8957092
    Abstract: A compound of formula 6-(methylcarbamoyl)-4-[(4-methylphenyl)amino]quinoline-3-carboxylic acid, and pharmaceutically acceptable salts thereof, is provided. The compound can be used to treat cancer, diabetic retinopathy, age-related macular degeneration, inflammation, stroke, ischemic myocardium, atherosclerosis, macular edema and psoriasis.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: February 17, 2015
    Assignee: ClanoTech AB
    Inventors: Jacob Westman, Natalia Nekhotiaeva, Johan Wannberg, Ulrika Backman, Johan Malm